Literature DB >> 31641341

A Simplified Algorithm for the Management of Hepatitis C Infection.

Douglas T Dieterich1.   

Abstract

Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of the World Health Organization. Official treatment guidelines are comprehensive and may be most appropriate for experienced treaters of HCV; however, global elimination of HCV infection will require the engagement of frontline health care providers (HCPs) to increase the capacity to treat patients. Thus, a simplified treatment algorithm is needed to provide guidance to non-HCV specialists. To accomplish this, a panel of 13 HCV specialists held a consensus meeting in September 2018 to create an easy-to-use, effective, safe, and scalable algorithm for the management and treatment of HCV infection through discussion and collective decision-making. The algorithm begins with universal HCV screening and diagnosis by testing for HCV antibody with reflex to polymerase chain reaction to detect HCV RNA. The pretreatment evaluation uses platelet-based stratification to initially assess fibrosis, and the pan-genotypic regimens glecaprevir/pibrentasvir or sofosbuvir/velpatasvir are recommended for treatment. Unless clinically indicated, on-treatment monitoring is optional. Confirmation of cure (undetectable HCV RNA 12 weeks posttreatment) is followed by harm-reduction measures, as well as surveillance for hepatocellular carcinoma every 6 months in patients with advanced fibrosis/cirrhosis. This algorithm provides guidance for management of uncomplicated cases of HCV by frontline HCPs and indicates when referral to an HCV specialist is warranted. The algorithm was created to enable more HCPs to screen for and manage HCV infection, and thus contribute to its elimination.
Copyright © 2019, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Hepatitis C; glecaprevir/pibrentasvir; simplified treatment; sofosbuvir/velpatasvir

Year:  2019        PMID: 31641341      PMCID: PMC6799873     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  39 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

Review 2.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-12-16

3.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Authors:  Tarik Asselah; Kris V Kowdley; Neddie Zadeikis; Stanley Wang; Tarek Hassanein; Yves Horsmans; Massimo Colombo; Filipe Calinas; Humberto Aguilar; Victor de Ledinghen; Parvez S Mantry; Christophe Hezode; Rui Tato Marinho; Kosh Agarwal; Frederik Nevens; Magdy Elkhashab; Jens Kort; Ran Liu; Teresa I Ng; Preethi Krishnan; Chih-Wei Lin; Federico J Mensa
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-22       Impact factor: 11.382

4.  Standard liver tests.

Authors:  George Kasarala; Hans L Tillmann
Journal:  Clin Liver Dis (Hoboken)       Date:  2016-07-26

5.  Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.

Authors:  Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Larry A Mole; Lisa I Backus
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

6.  EASL Recommendations on Treatment of Hepatitis C 2018.

Authors: 
Journal:  J Hepatol       Date:  2018-04-09       Impact factor: 25.083

7.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.

Authors:  Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-08-11       Impact factor: 9.079

Review 8.  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 9.  Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.

Authors:  Marcus M Mücke; Lisa I Backus; Victoria T Mücke; Nicola Coppola; Carmen M Preda; Ming-Lun Yeh; Lydia S Y Tang; Pamela S Belperio; Eleanor M Wilson; Ming-Lung Yu; Stefan Zeuzem; Eva Herrmann; Johannes Vermehren
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-01-19

10.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

View more
  10 in total

1.  Impact of Coronavirus Disease 2019 Pandemic on Viral Hepatitis Elimination: What Is the Price?

Authors:  Leonard Sowah; Christine Chiou
Journal:  AIDS Res Hum Retroviruses       Date:  2021-06-02       Impact factor: 1.723

2.  Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.

Authors:  Alessandra Mangia; Scott Milligan; Mandana Khalili; Stefano Fagiuoli; Stephen D Shafran; Fabrice Carrat; Denis Ouzan; George Papatheodoridis; Alnoor Ramji; Sergio M Borgia; Heiner Wedemeyer; Ruggero Losappio; Francisco Pérez-Hernandez; Nicole Wick; Robert S Brown; Pietro Lampertico; Karen Doucette; Ioanna Ntalla; Heribert Ramroth; Michael Mertens; Kim Vanstraelen; Juan Turnes
Journal:  Liver Int       Date:  2020-06-09       Impact factor: 5.828

3.  Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.

Authors:  Bassem Asker; Raghad Jawad; Rabah Asreah; Haydar Jamal; Ahmed Jassem; Muslim Abdelkareem Inaya; Hiwa Abou Baker; Sam Kozma; Eid Mansour; Bryony McNamara; Ryan Miller; Oliver Darlington; Phil McEwan; Daniel M Sugrue; Haidar Jarallah
Journal:  Pharmacoeconomics       Date:  2021-08-16       Impact factor: 4.981

4.  The impact of COVID-19 on the cascade of care of HCV in the US and China.

Authors:  Yee Hui Yeo; Xu Gao; Jian Wang; Qingyu Li; Xingyang Su; Yu Geng; Rui Huang; Chao Wu; Fanpu Ji; Vinay Sundaram; Mazen Noureddin; Maria Buti; Walid S Ayoub
Journal:  Ann Hepatol       Date:  2022-02-19       Impact factor: 3.388

5.  Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice.

Authors:  Farihah Malik; Vladimir Chulanov; Nikolay Pimenov; Anastasia Fomicheva; Rebecca Lundin; Nataliia Levina; Claire Thorne; Anna Turkova; Giuseppe Indolfi
Journal:  J Virus Erad       Date:  2022-02-03

Review 6.  HCV treatment in 2020: How to translate highly effective therapies into elimination strategies.

Authors:  Omar Alshuwaykh; Paul Y Kwo
Journal:  Hepatol Forum       Date:  2020-05-21

7.  Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel.

Authors:  Vito Fiore; Giuseppe De Matteis; Emanuele Pontali; Andrea De Vito; Sandro Panese; Nicholas Geremia; Ivana Maida; Stefania Artioli; Giulio Starnini; Giordano Madeddu; Sergio Babudieri
Journal:  Front Public Health       Date:  2022-10-04

8.  Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.

Authors:  Jaspreet Banga; Sobia Nizami; Jihad Slim; Sandhya Nagarakanti; Mario Portilla; Shobha Swaminathan
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

9.  Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center.

Authors:  Sarah A Rojas; Job G Godino; Adam Northrup; Maureen Khasira; Aaron Tam; Lisa Asmus; Catherine Frenette; Christian B Ramers
Journal:  Hepatol Commun       Date:  2020-12-21

10.  Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences.

Authors:  Joaquin Cabezas; Susana Llerena; Miguel Mateo; Rocío Álvarez; Carmen Cobo; Victoria González; Elisa Martró; Antonio Cuadrado; Javier Crespo
Journal:  Diagnostics (Basel)       Date:  2021-05-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.